This advancement in technology facilitated the detection of further fusions, e.g. the EML4-ALK fusion (Soda et al., 2007) in lung cancer and the TMPRSS2-ERG fusion (Tomlins et al., 2007) in prostate cancer. Here, TMPRSS2 is linked to prostate cancer.